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http://dxObjective: Acute kidney injury is a common clinical complication of cardiac surgery. Volatile anesthetics have
been shown to protect against it in animal experiments. Clinically, however, the effect of volatile anesthetics has
been unclear. We conducted a systematic review and meta-analysis of randomized, controlled trials to explore
whether volatile anesthetics could provide renal protection to patients undergoing cardiac surgery.
Methods: Randomized, controlled trials were identified in PubMed, Ovid, Excerpta Medica Database,
Cochrane Library, Current Controlled Trials Register, reviews, and reference lists of relevant articles. Ten trials
with 1600 total participants were eligible. Data were analyzed with both fixed- and random-effects models.
Results: Relative to control data, volatile anesthetics significantly reduced acute kidney injury incidence
(relative risk [RR], 0.65; 95% confidence interval [CI], 0.43-0.97; P ¼ .04). Although there was no significant
difference between groups in absolute postoperative serum creatinine level and mortality, patients receiving
volatile anesthetics had significantly (or borderline) lower increase in serum creatinine level from baseline on
the first (weighted mean difference, 0.04 mg/dL; 95% CI, 0.07 to 0.01 mg/dL; P ¼ .002) and second
(weighted mean difference, 0.07 mg/dL, 95% CI, 0.14 to 0.00 mg/dL; P ¼ .05) postoperative days
and reduced incidences of prolonged intensive care unit stay (RR, 0.46; 95% CI, 0.34-0.64; P< .001) and
hospitalization (RR, 0.47; 95% CI, 0.27-0.83; P ¼ .009).
Conclusions: Current evidence shows that volatile anesthetics may provide renal protection in patients
undergoing cardiac surgery and supports further randomized, controlled trials with larger sample sizes and
high methodologic quality. (J Thorac Cardiovasc Surg 2014;148:3127-36)See related commentary on pages 3137-8.Acute kidney injury (AKI), characterized by a rapid fall in
glomerular filtration rate and accumulation of nitrogenous
waste products, remains a common complication of heart
surgery.1,2 Postoperative AKI affects as many as 45% of
patients undergoing cardiac surgery and has been
associated with prolonged hospitalization and increased
mortality.3-5 In clinical practice, renal ischemia-reperfusion
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MAKI.6 Agents that can attenuate IR injury have therefore
been sought and studied.7
Volatile anesthetics are commonly used for general
anesthesia during surgery to induce and maintain
hypnosis, analgesia, and amnesia and to produce mild mus-
cle relaxation. In addition to their anesthetic effects, volatile
anesthetics are believed to have significant nonanesthetic
physiologic effects.8,9 An increasing body of evidence has
convincingly demonstrated that volatile anesthetics can
protect against IR injury in the heart.8,10 The mechanisms
of cardioprotective effects have been suggested to be
related to ischemic preconditioning effect induced by
volatile anesthetics.11,12 Because the preconditioning
holds the characteristic of cross-tolerance, the protective
effects of volatile anesthetics may extend to other organ
systems subject to IR injury.9 Volatile anesthetics have
therefore been hypothesized to have renal protection
potential in cardiac surgery. Moreover, the protection of
volatile anesthetics against IR-induced renal injury has
been confirmed by a number of animal studies.13-15 The
clinical studies regarding the protective effects of volatile
anesthetics against AKI in patients undergoing cardiac
surgery have been limited, however, and the results have
remained controversial.16,17 In this meta-analysis of
randomized controlled trials (RCTs), we aimed to assess
the effectiveness of volatile anesthetics for renal protection
in patients undergoing cardiac surgery.diovascular Surgery c Volume 148, Number 6 3127
Abbreviations and Acronyms
AKI ¼ acute kidney injury
CI ¼ confidence interval
ICU ¼ intensive care unit
IR ¼ ischemia-reperfusion
RCT ¼ randomized, controlled trial
RR ¼ relative risk
TIVA ¼ total intravenous anesthesia
WMD ¼ weighted mean difference
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Search Strategy
The literature search was performed on PubMed, the Ovid information
system, the Excerpta Medica Database (EMBASE), and the Cochrane
Library through January 2014. Complex search strategies were formulated
with the followingMedical Subject Headings (MeSH) terms and text words:
inhalation anesthetic, halogenated anesthetic, volatile anesthetic, sevoflur-
ane, desflurane, isoflurane, enflurane, halothane, cardiac surgery, heart sur-
gery, mitral valve, aortic valve, coronary surgery, coronary artery bypass
graft, and cardiopulmonary bypass. To find any studiesmissed by these liter-
ature searches, we hand searched reference lists of all eligible studies and
relevant review articles. In addition, we searched for unpublished and
ongoing trials in clinical trial registries (ClinicalTrials.gov, Controlled-
trials.com, and the World Health Organization International Clinical Trials
Registry Platform). Searches were not restricted by language, date pub-
lished, or publication status. Duplicate reports were eliminated.
Study Selection
We included studies when the following criteria were met: (1) RCTs,
(2) studies conducted in a cardiac surgical population, (3) intervention
consisting of an anesthesia plan including administration of any volatile
anestheticswithout restriction indose and timeof administration, (4) patients
in the comparator arm receiving total intravenous anesthesia (TIVA), (5)
availability of measurements of serum creatinine concentrations at baseline
and follow-up or postoperative AKI incidence. Trials were excluded if they
did not conform to these criteria or when children were involved.
Data Extraction
Two reviewers (D. X. and C. J.) assessed the eligibility of studies in
duplicate and independently by means of a standardized form developed
for this purpose. Disagreements were adjudicated by a third reviewer.
Data extraction was done by the same observers with a standardized data
extraction form developed for this study. The following informationwas ex-
tracted from each study: study and patient characteristics, anesthetic
protocol, volatile anesthetic dosage and treatment duration, choice and
dosage of intravenous anesthetics, duration of cardiopulmonary bypass, car-
dioplegic technique, hypothermic condition, target mean arterial pressure,
inotrope therapy, the incidence of AKI, mortality, rates of prolonged inten-
sive care unit (ICU) stay and hospitalization, and levels of kidney injury bio-
markers (serum creatinine and cystatin C). Several studiesmet our inclusion
criteria but were missing data vital to our analyses (eg, means and SDs); we
therefore contacted the authors to obtain raw data whenever possible. For
studies involving 2 intervention arms that had 2 different volatile or intrave-
nous anesthetics, data were analyzed according methods described in the
Cochrane Handbook for Systematic Reviews of Interventions.
Quality Assessment
According to standard criteria established by J€uni and colleagues,18 2
independent reviewers (D. X. and C. J.) assessed aspects of the reported3128 The Journal of Thoracic and Cardiovascular Surmethodologic quality of each included study pertaining to generation of
randomized sequences, concealment of treatment allocation schedules,
blinding of outcome assessments, and adequacy of follow-up.
Statistical Analysis
Statistical analyses in this study were carried out with RevMan software
(version 5.2; The Cochrane Collaboration; Oxford, UK). The primary
outcomes of this study were the level and change of creatinine after surgery
and the development of AKI. For assessment of the change in the creatinine
level from baseline, the unbiased estimator of variance method in the
Cochrane Handbook was used to calculate the SD. In studies in which
medians were reported, means and SDs were estimated if we could not
get the raw data from the authors.19 Continuous outcomes were calculated
as weighted mean differences (WMDs), and dichotomous outcomes were
calculated as relative risks (RRs), with their respective 95% confidence
intervals (CIs). The pooled WMD and common RR with 95% CI values
for all studies were computed according to both fixed- and random-
effects models; the latter was more conservative where heterogeneity
beyond that expected by chance alone was encountered. The c2 test was
used to estimate heterogeneity across the studies, with a value of 50% or
more indicating a substantial level of inconsistency. A planned subgroup
analysis was performed according to the choice of volatile anesthetic.
RESULTS
Search Strategy
The initial literature search identified 2322 potentially
relevant citations (Figure 1), of which 2218 were excluded
after independent review of the title and abstract. The
remaining 104 articles were considered of interest and
examined in full text. Of these, 68 were excluded from
the meta-analysis (review articles, non-RCTs, irrelevant to
our aim). After assessment in more detail, 26 of the
remaining 36 RCTs were excluded because 25 did not
report postoperative serum creatinine value or incidence
of AKI and 1 lacked a TIVA control group. The remaining
10 RCTs were included in the systematic review.16,20-28
Characteristics of Included Studies
Table 1 summarizes the main features of the included
studies. A total of 1600 patients (860 allocated to receive vol-
atile anesthetics and 740 receiving TIVA in their anesthesia
plan) were enrolled in the 10 studies, and the sample sizes
were 22 to 354 participants of each study. Six trials were per-
formed on patients undergoing coronary surgery, and the
other 4 studies were performed on patients undergoing aortic
or mitral valve surgery. Volatile anesthetics were adminis-
trated throughout the procedure in 7 of the involved studies,
whereas in 3 of them volatile anesthetics administered for a
short time and only before, during, or after the cardiopulmo-
nary bypass. Theminimumalveolar concentration of volatile
anesthetics was always at least 0.15 and ranged from 0.15 to
2. There were no significant differences between the groups
with regard to age, sex, comorbidities (hypertension and dia-
betes), and preoperative renal status.
The intraoperative and postoperative characteristics of
the involved studies are presented in Table 2. Most studies
were performed on patients undergoing cardiac surgerygery c December 2014
FIGURE 1. Flow diagram of trial search and selection progress. RCT, Randomized, controlled trial; AKI, acute kidney injury; TIVA, total intravenous
anesthesia.
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Mwith cardiopulmonary bypass, and only 1 study investigated
patients undergoing off-pump coronary artery bypass
grafting.23 In these studies, cardiopulmonary bypass was
conducted under hypothermic conditions (28C-36C),
and the cardiopulmonary bypass time was comparable
between the volatile anesthetic and control groups
(P ¼ .21). Four studies mentioned the cardioplegic tech-
niques; in all of these, cold blood or cardioplegic solution
was applied. In most trials, the target mean arterial pressure
was set to greater than 50 to 65mmHg; otherwise, inotropic
or vasoactive support would be required. Compared with
TIVA group, use of volatile anesthetics was also associated
with a significant reduction in need for inotrope therapyThe Journal of Thoracic and Car(P<.001). Postoperatively, 7 trials reported the incidence
of AKI according to the level of serum creatinine or
cystatin C.
Quality Assessment
Table 3 describes the methodologic quality of the RCTs.
The overall methodologic quality of the included RCTs was
good. All included studies randomly allocated their
patients, and 8 of them described adequate methods to
generate randomized sequences and had concealed the
randomization allocations. Only 2 trials did not confirm
the use of blinded outcome assessors. All 10 trials reported
adequate details of withdrawals and dropouts in each group.diovascular Surgery c Volume 148, Number 6 3129
TABLE 1. Main features of studies included in meta-analysis (volatile anesthetic group and total intravenous anesthesia group)
Study
Sample
size (n)
Mean
age (y)
Male
(%)
Comorbidities
Surgical
procedure
Volatile
anesthetic
Adminis-
tration MAC TIVA Dosage
Baseline creatinine
(mg/dL; mean ± SD)
HTN
(no.)
Diabetes
(no.)
Volatile
anesthetic TIVA
Bignami et al,20
2012
50/50 67/66 74/78 28/29 5/1 MVR Sevo Pre-CPB,
post-CPB
0.5-2 Propofol 2-3 mg/kg/h 1.05  0.69 0.98  0.25
Cho et al,21 2009 15/15 57/48 20/20 7/6 2/3 MVR,
AVR
Sevo Whole
procedure
0.75-1.25 Sufentanil þ
midazolam
2.0-2.2
mg/kg/h;
0.08
mg/kg/h
NR NR
De Hert et al,22
2004
160/160 67/67 82/81 NR 44/46 Coronary
surgery
Sevo; Des Whole
procedure
0.15-1 Propofol,
midazolam
2-4 mg/mL;
0.1-1.5
mg/kg/mL
NR NR
Guarracino
et al,23 2006
57/55 69/69 86/78 NR 14/13 OPCAB Des whole
procedure
0.5-2 Propofol 2-3 mg/kg/h 1.3  0.36 1.3  0.80
Jovic et al,24
2012
11/11 63/63 45/73 8/7 1/2 AVR Sevo Whole
procedure
1-2 Propofol 6-10 mg/kg/h NR NR
Julier et al,16
2003
37/35 62/65 84/80 26/22 9/9 CABG Sevo During CPB
10 min
2 Propofol 2-5 mg/mL 0.98  0.24 0.97  0.23
Landoni et al,25
2007
59/61 62/59 59/50 17/19 NR MV
surgery
Des During CPB
30 min
0.5-2 Propofol 2-3 mg/kg/h 0.9  0.24 0.9  0.25
Lorsomradee
et al,26 2006
160/160 67/66 86/75 NR 39/50 CABG Sevo Whole
procedure
0.25-1 Propofol 2-4 mg/mL 1.1  0.3 1.0  0.2
Story et al,27
2001
236/118 67/65 81/84 NR 57/42 CABG Sevo; Iso Whole
procedure
Sevo, 0.5-2;
Iso, 0.25-1
Propofol 1-8 mg/mL Sevo, 1.13  0.28;
Iso, 1.09  0.22
1.10  0.22
Tritapepe et al,28
2007
75/75 64/66 84/80 NR 18/13 CABG Des Whole
procedure
1 Propofol 2-3 mg/mL 1.1  0.42 1.1  0.30
HTN, Hypertension; MAC, minimum alveolar concentration; TIVA, total intravenous anesthesia; MVR, mitral valve replacement; Sevo, sevoflurane; CPB, cardiopulmonary
bypass; AVR, aortic valve replacement; NR, not reported;Des, desflurane; OPCAB, off-pump coronary artery bypass grafting; CABG, coronary artery bypass grafting;MV, mitral
valve; Iso, isoflurane; SD, standard deviation.
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MEffects of Volatile Anesthetics on Postoperative Renal
Function and Clinical Outcomes
Incidences of AKI and renal replacement therapy.
There were 7 trials included in the meta-analysis that
reported the incidence of AKI. AKI was defined differently
among the involved studies. Three studies used a
postoperative increase in serum creatinine greater than
100%, 1 study used a prospectively defied cutoff
concentration of greater than 1.5 mg/L for cystatin C, and
the remaining studies regarded peak serum creatinine level
greater than 1.5 mg/dL or at least 2.0 mg/dL as their
primary definition of AKI. The overall results based on a
fixed-effects model showed that, relative to the control
group, the use of volatile anesthetics significantly reduced
the risk of AKI (RR, 0.65; 95% CI, 0.43-0.97; P ¼ .04;
I2 ¼ 0%; Figure 2, A). To investigate whether the type of
volatile anesthetic would influence the effectiveness,
subgroup analysis by desflurane versus sevoflurane was
performed. The reduction of AKI incidence was significant
with sevoflurane (RR, 0.49; 95% CI, 0.25-0.97; P ¼ .04;
I2 ¼ 36%; Figure 2, A), which was the same as the overall
result. Although a reduced risk of AKI was not found
in studies for the use of desflurane (RR, 0.77; 95% CI,
0.47-1.27; P ¼ .30; I2 ¼ 0%; Figure 2, A), there was no
significant difference between patients receiving these 2
types of volatile anesthetic (P ¼ .29). Furthermore,3130 The Journal of Thoracic and Cardiovascular Surinformation on renal replacement therapy was available
for 2 studies. No significant difference was detected in the
incidence of renal replacement therapy between the volatile
anesthetic and TIVA groups (RR, 1.20; 95% CI, 0.28-5.15;
P ¼ .81; I2 ¼ 0%; Figure 2, B).
Biomarkers of kidney injury. The mean levels of serum
creatinine ascertained at ICU arrival and on the first and
second postoperative day were assessed. The serum
creatinine levels at ICU arrival (WMD, 0.00 mg/dL; 95%
CI, 0.04 to 0.04 mg/dL; P ¼ .94; I2 ¼ 0%; Figure 3, A),
on the first postoperative day (WMD, 0.01 mg/dL, 95%
CI, 0.05 to 0.03 mg/dl; P ¼ .64; I2 ¼ 0%; Figure 3, B),
and on the second postoperative day (WMD, 0.05
mg/dL; 95% CI, 0.10 to 0.00 mg/dL; P ¼ .07;
I2 ¼ 0%; Figure 3, C) did not differ evidently between
the volatile anesthetic and control groups. In addition, we
compared mean changes from baseline in serum creatinine
levels between the control and treatment groups. Relative to
TIVA, the overall pooled results showed that volatile
anesthetics did not bring a significant change in creatinine
level at the ICU arrival (WMD, 0.04 mg/dL; 95% CI,
0.10 to 0.02 mg/dL; P ¼ .18; I2 ¼ 73%; Figure 4, A).
Patients who received volatile anesthetics did, however,
have significantly (or borderline) lower increase in serum
creatinine level from baseline on the first postoperative
day (WMD, 0.04 mg/dL; 95% CI, 0.07 to 0.01gery c December 2014
TABLE 2. Intraoperative and postoperative characteristics of studies included in meta-analysis (volatile anesthetic group and total intravenous
anesthesia group)
Study
CPB time
(min, mean ± SD)
Cardioplegic
technique
Hypothermic
condition
(C)
Target MAP
(mm Hg)
Intraoperative
inotropes
Postoperative
inotropes
AKI
definition
AKI
incidence
Volatile
anesthetic TIVA
Bignami et al,20
2012
104  21 97  27 Cold blood 32-34 >65 25/29 33/38 NR NR
Cho et al,21 2009 129  24 131  25 NR 28 20% of
baseline
5/6 6/7 SCr>2.0
mg/dL
2/2
De Hert et al,22
2004
97  28 96  31 NR 32 >60 40/80 49/91 SCr>1.5
mg/dL
15/17
Guarracino
et al,23 2006
NR NR NR NR NR NR 20/31 100% SCr
increase
3/4
Jovic et al,24
2012
90  25 92  21 NR 32 50-70 NR 2/3 SCr>1.5
mg/dL
2/0
Julier et al,16
2003
116  32 106  31 Cold
cardioplegic
solution
32 >50 NR NR Cystatin C
>1.5 mg/L
2/10
Landoni et al,25
2007
83  24 84  25 Cold blood 32-34 >65 38/37 25/33 100% SCr
increase
10/13
Lorsomradee
et al,26 2006
97  28 98  29 NR 36 60-80 36/78 44/90 NR NR
Story et al,27
2001
Sevo,
92  23;
Iso, 98  23
101  24 NR NR 60-80 NR NR NR NR
Tritapepe et al,28
2007
90  28 97  34 Cold blood 32-34 NR NR 24/31 100% SCr
increase
5/4
CPB, Cardiopulmonary bypass; TIVA, total intravenous anesthesia; MAP, mean arterial pressure, AKI, acute kidney injury; NR, not reported; SCr, serum creatinine;
Sevo, sevoflurane; Iso, isoflurane; SD, standard deviation.
Cai et al Perioperative Managementmg/dl; P ¼ .002; I2 ¼ 25%; Figure 4, B) and the second
postoperative day (WMD, 0.07 mg/dL; 95% CI, 0.14
to 0.00 mg/dl; P ¼ .05; I2 ¼ 72%; Figure 4, C). Moreover,
there were 2 studies that analyzed cystatin C, a more sensi-
tive marker of renal injury, in both groups postoperatively.
Results showed that the lower level of cystatin C on the first
postoperative day associated with volatile anesthetics was
of borderline statistical significance (WMD, 0.10 mg/L;
95% CI, 0.21 to 0.00 mg/dL; P ¼ .06; I2 ¼ 0%;
Figure 3, D).TABLE 3. Methodologic quality assessment of randomized controlled tria
Study
Adequate method to
generate randomized
sequence
Adequate me
of allocatio
concealme
Bignami et al,20 2012 Y Y
Cho et al,21 2009 N N
De Hert et al,22 2004 Y Y
Guarracino et al,23 2006 Y Y
Jovic et al,24 2012 N N
Julier et al,16 2003 Y Y
Landoni et al,25 2007 Y Y
Lorsomradee et al,26 2006 Y Y
Story et al,27 2001 Y Y
Tritapepe et al,28 2007 Y Y
The Journal of Thoracic and CarProlonged ICU stay, prolonged hospitalization, and
mortality. Information about the incidences of prolonged
ICU stay (>48-72 hours) and prolonged hospitalization
(7-15 days) were available for 4 and 3 trials involved in
the meta-analysis, respectively, whereas mortalities were
reported in 8 studies. Relative to TIVA, the numbers of
patients who needed prolonged ICU stays (RR, 0.46; 95%
CI, 0.34-0.64; P < .001; I2 ¼ 0%; Figure 5, A) and
prolonged hospitalization (RR, 0.47; 95% CI, 0.27-0.83;
P ¼ .009; I2 ¼ 35%; Figure 5, B) were significantly lowerls included in this study
thod
n
nt
Blinding of
outcome
assessors
Explanation for
withdrawals or
dropouts
All patients
treated in
assigned group
Y Y Y
N Y Y
Y Y Y
Y Y Y
N Y Y
Y Y Y
Y Y Y
Y Y Y
Y Y Y
Y Y Y
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FIGURE 2. Forest plot of relative risks in the incidence of AKI (A) and renal replacement therapy (B). TIVA, Total intravenous anesthesia;
M-H, Mantel-Haenszel (log-rank); CI, confidence interval.
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Mwith the volatile anesthetics. There was, however, no
statistically significant difference in the all-cause mortality
between the groups (RR, 0.44; 95% CI, 0.14-1.33; P¼ .14;
I2 ¼ 0%; Figure 5, C).
DISCUSSION
In this meta-analysis of 10 RCTs involving 1600 patients
who underwent heart surgery, our results generally
indicated a positive effect of volatile anesthetic use on renal
function and relevant clinical outcomes. Our primary
outcomes were the differences between volatile anesthetics
and TIVA groups in the incidence of AKI and the level and
change of renal injury biomarkers during follow-up. We
found that volatile anesthetics significantly improved the
change from baseline in the level of serum creatinine and
were associated with obvious reductions in the incidence
of AKI, although there were no differences in the absolute
serum creatinine levels and the rate of renal replacement
therapy between the control and treatment groups. More-
over, the pooled results of these trials also indicated a
benefit of volatile anesthetics for significantly decreasing
the proportion of patients with prolonged ICU stay and
hospitalization and demonstrated a slight trend toward
reduced all-cause mortality.
In addition to their wide use in clinical practice for
general anesthesia, volatile anesthetics have been found to
induce a beneficial effect termed anesthetic precondition-
ing, which shares several common mechanisms of action
with ischemic preconditioning.11,12,29 Because of their3132 The Journal of Thoracic and Cardiovascular Surprotective effects on organs under IR injury through
anesthetic preconditioning, volatile anesthetics have
primarily been reported to have cardioprotective
properties and to ameliorate heart IR injury in cardiac and
vascular interventions. AKI is another frequent
complication of heart surgery and is also mainly caused
by IR damage. Because ischemic preconditioning has
been demonstrated in organs other than the heart,
anesthetic preconditioning might also offer the potential
for renal protection in cardiac surgery. Furthermore, in
addition to anesthetic preconditioning, volatile anesthetics
might protect the kidney from IR injury by providing
more stable hemodynamic responses.8,30 It has been
confirmed that, in addition to cardiopulmonary bypass–
induced ischemia, hemodynamic instability also plays
important role in the pathogenesis of postoperative AKI.31
In our analysis of the characteristics of the involved studies,
significant reduction in need for intraoperative and
postoperative inotrope therapy was found in the volatile
anesthetic group, which confirmed that volatile anesthetic
administration was associated with better hemodynamic
stability.
Our results demonstrated that volatile anesthetics
administration significantly reduced the incidence of AKI
after cardiac surgery. Therewas no uniformly accepted defi-
nition of postoperative AKI (Table 2). A relative increase
greater than 100% from baseline in serum creatinine or
an absolute level greater than 1.5 to 2.0 mg/dL after cardiac
surgery was used in most of the included trials. Only in thegery c December 2014
FIGURE 3. Forest plot of weighted mean differences in the levels of renal biomarkers. A, Serum creatinine level at intensive care unit arrival.
B, Serum creatinine level on the first postoperative day. C, Serum creatinine level on the second postoperative day. D, Serum cystatin C level on the first
postoperative day. TIVA, Total intravenous anesthesia; IV, instrumental variable; CI, confidence interval; SD, standard deviation.
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Mstudy by Julier and colleagues16 was postoperative renal
dysfunction defined according to the level of cystatin C.
Although no significant statistical heterogeneity was found
in the meta-analysis of AKI incidence, there would be no
significant difference in the rate of AKI between patients
with volatile anesthetics and those with TIVA when we
excluded the data from the study of Julier and colleagues.16
To address the variability related to the absence of a uniform
definition of AKI, we compared the incidence of renal
replacement therapy between the treatment and control
groups. Supportive renal replacement therapy, the only
treatment option currently available for AKI, has alsoThe Journal of Thoracic and Carbeen recommended as a hard end point in studies of AKI af-
ter cardiac surgery.32 Only 2 studies reported the rate of
renal replacement therapy, however, and no significant
improvement in the rate of renal replacement therapy was
found.
We evaluated postoperative renal function with serum
creatinine value (both absolute level and change from
baseline). When analyzed in term of the absolute serum
creatinine level, there was no significant difference between
the treatment and control groups. It was noted, however,
that patients receiving volatile anesthetics had an apparent
trend toward lower serum creatinine level on the seconddiovascular Surgery c Volume 148, Number 6 3133
FIGURE 4. Forest plot of weighted mean differences in the change of serum creatinine level from baseline at intensive care unit arrival (A), on the first
postoperative day (B), and on the second postoperative day (C). TIVA, Total intravenous anesthesia; IV, instrumental variable; CI, confidence interval;
SD, standard deviation.
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Mpostoperative day. With regard to the change from baseline,
patients who received volatile anesthetics had a signifi-
cantly smaller rise in creatinine level on the first and second
postoperative days. It has been reported that the degree of
creatinine elevation is more important than the absolute
level of creatinine for estimating death risk in patients
with AKI, and even a small increase in creatinine after
cardiac surgery is correlated with increased duration
and cost of hospitalization and with the short-term risk
of mortality.33-35 In addition, renal injury was also
assessed with the postoperative measurement of serum
cystatin C concentration. As opposed to serum creatinine
concentration, cystatin C level is independent of age, sex,
muscle mass, or dietary factors, and it more readily and
accurately reflects even mild renal dysfunction.36 Results
from our current systematic review suggested that there
was a borderline significantly lower level of cystatin C in
the volatile anesthetic group. Consistent with improvement
in postoperative renal function, volatile anesthetic adminis-
tration significantly reduced the incidences of prolonged3134 The Journal of Thoracic and Cardiovascular SurICU stay and prolonged hospitalization and slightly,
although not significantly, decreased mortality.
Except for a single studywith isoflurane, the volatile anes-
thetic choice for patients in the studies included in this review
was desflurane or sevoflurane. To address the question of
whether the choice of anesthetic regimenmight influence pa-
tients’ outcome, we conducted a subgroup analysis. We
found a significant trend toward reduced AKI among the pa-
tients who received sevoflurane, whereas no such trend was
evident among the patients who received desflurane. In ani-
mal studies, Lee and coworkers37 has shown that the degree
of renal protection by desflurane was significantly less than
that conferred by sevoflurane, which was thought be related
to their different properties in promoting attenuation of
cellular injury and functional recovery.38 Because of the
limited number of trials with desflurane, however, we failed
to determine whether desflurane and sevoflurane were asso-
ciated with different changes in renal biomarkers.
The strengths of this systematic review include the use of
strict methodologic inclusion criteria, a quality assessmentgery c December 2014
FIGURE 5. Forest plot of relative risks in the incidences of prolonged intensive care unit stay (A), prolonged hospitalization (B), and all-cause mortality
(C). TIVA, Total intravenous anesthesia; M-H, Mantel-Haenszel (log-rank); CI, confidence interval.
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Mof all clinical trials, and its ability to garner a sufficiently
large study population in this area dominated by relatively
small studies. On the other hand, there are several potential
limitations of this meta-analysis. First, as mentioned
previously, various definitions have been proposed for
postoperative AKI. Although there was not considerable
heterogeneity among the included studies, these data do
not yet allow any firm conclusions. Second, there was a
significant level of variability in the time and duration of
volatile anesthetic administration, and because of a lack
of available data in a usable format, a subgroup analysis
could not be performed. Third, publication bias cannot be
excluded. We did not test for publication bias with funnel
plots or other statistical tests, because such tests are
unreliable in the presence of a small number of studies.
We did, however, undertake an effort to minimize publica-
tion bias by including broad search and inclusion criteria,The Journal of Thoracic and Carhand searching the references, and contacting the authors
of the primary trials.
We thank the investigators of the original studies for generously
sharing their data with us.References
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